Zevra Therapeutics (NASDAQ:ZVRA) Stock: Insider Neil Mcfarlane Sells 20,000 Shares

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CEO Neil Mcfarlane sold 20,000 shares of the stock in a transaction on Monday, October 12th. The stock was sold at an average price of $11.25, for a total value of $225,000.00. Following the completion of the transaction, the chief executive officer owned 417,225 shares of the company’s stock, valued at approximately $4,693,781.25. This trade represents a 4.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zevra Therapeutics Trading Down 1.5%

Shares of Zevra Therapeutics stock opened at $10.23 on Thursday. The firm has a market capitalization of $607.46 million, a P/E ratio of 6.58 and a beta of 0.98. The business has a fifty day simple moving average of $11.53 and a two-hundred day simple moving average of $11.41. Zevra Therapeutics, Inc. has a 12 month low of $8.01 and a 12 month high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. The firm had revenue of $39.66 million for the quarter, compared to the consensus estimate of $33.88 million. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. Analysts predict that Zevra Therapeutics, Inc. will post 0.72 earnings per share for the current year.

Hedge Funds Weigh In On Zevra Therapeutics

Several large investors have recently modified their holdings of ZVRA. AIGH Capital Management LLC bought a new stake in Zevra Therapeutics during the 1st quarter valued at about $11,184,000. Bank of New York Mellon Corp purchased a new position in Zevra Therapeutics in the second quarter worth about $2,846,000. Hennion & Walsh Asset Management Inc. raised its holdings in Zevra Therapeutics by 116.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock worth $5,502,000 after buying an additional 206,543 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Zevra Therapeutics by 259.2% in the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after buying an additional 400,336 shares in the last quarter. Finally, Globeflex Capital L P bought a new position in shares of Zevra Therapeutics in the second quarter worth approximately $2,752,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on ZVRA. HC Wainwright restated a “buy” rating and issued a $26.00 price objective on shares of Zevra Therapeutics in a report on Thursday, August 20th. Guggenheim lowered their target price on shares of Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating for the company in a report on Friday, August 7th. BTIG Research lowered their target price on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating for the company in a report on Monday, July 27th. Citizens Jmp boosted their price target on Zevra Therapeutics from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, August 6th. Finally, UBS Group restated a “buy” rating on shares of Zevra Therapeutics in a research note on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $27.14.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.